Day One

Wednesday 17th April 2024

8:00 am Registration & Morning Coffee

8:55 am Chair’s Opening Remarks

8:56 am
Uncovering New Targetable Pathways in Inflammatory-Mediated Disease: Forming the Basis for Developing Safe & Effective Therapies

9:00 am Itch, a Strategic Target for Treatment of Type 2 Skin Diseases


• Understanding shared and unique characteristics of AD, PN and CSU

• Describe the contribution of type 2 inflammation to neuroimmune dysregulation and itch in AD, PN, and CSU

• Improvement of itch and disease control with IL-4R across type 2 inflammatory skin disease

9:30 am Topical Biologics for the Treatment of Inflammatory Disorders Including Pruritus, AD, & Acne


• Discussion of the drug development evolution of a first-in-class therapy

• Results from previous Phase 2 studies

• Roadmapping what is next to bring these novel therapeutics to market

10:00 am Morning Break & Speed Networking


Meet and connect with your peers in this dedicated networking session

10:30 am Elevating Dermatological Drug Development Through Advanced Inflammatory Marker Targeting Methodology


• Speaking to preclinical study design to evaluate anti-interleukin 17 NanoAbs as a treatment for plaque psoriasis, which showed the downregulation of psoriasis molecular markers

• Leveraging 3D biologic skin models to mimic the structure of human skin to suggest NanoAbs’ therapeutic potential

• Demonstrating the potential for a systemic novel approach with higher affinity for IL-17F isoform to improve treatment efficacy for patients with psoriasis

10:32 am
Biomarkers in Dermatology: Building Better Patient Population Insights Into Drug Development Strategy Planning

11:30 am Biomarker-Driven Drug Development in Dermatology


• How leveraging and integrating methodologies, including RNA sequencing and multiomics approaches can verify drug pharmacodynamics, demonstrating efficacy and safety through biomarkers

• Investigator-initiated studies with approved drugs to validate novel endpoints

• Deep-phenotyping of patients with inflammatory skin diseases for stratification and improved disease understanding

• Case study with anti-IL-23 therapy for psoriasis, presenting recent outcomes using a technology driven approach

12:00 pm Lunch Break


Take this chance to meet the expert speakers, connect with your peers and explore our exhibition hall to meet fresh and familiar faces or even your next partner!

1:00 pm AI Assisted Objective Skin Imaging & Analysis of Skin Diseases & Drug Effects in Clinical Trials


• Standardised high quality mobile skin imaging

• Smart skin imaging data and objective image analysis

• Machine learning and AI powered decision support in trials and new digital skin biomarker and endpoints in HS and beyond

1:28 pm
Optimising Drug Delivery to Target Sites with Improved Stability & Bioavailability

1:30 pm Detailing Hedgehog-Signalling Inhibition as a Promising Target for Unmet Needs in the Dermatology Universe

  • Ofer Toledano Vice President - Research & Development, Sol Gel Technologies


• Exploring the mechanism of Patidegib a hedgehog inhibitor (HHI) blocker, preventing new basal cell carcinomas in Gorlin Syndrome

• Current data showcasing the potential of this mechanism and highlighting the benefits of topical HHIs over oral HHIs

2:00 pm Panel Session : Route of Administration & Formulations: How Can We Improve?

  • Ofer Toledano Vice President - Research & Development, Sol Gel Technologies
  • David Cook Chief Scientific Officer, Blueberry Therapeutics Ltd


Delving into the complexities of selecting appropriate routes of administration and formulation strategies, learn expert takes on:

• How can biopharma better formulate drugs effectively bypass of overcome the skin’s barrier function?

• What’s needed, from a drug delivery system perspective, to ensure optimal therapeutic outcomes and reduce potential side efects?

• What do biopharma developing therapeutics for immune-mediated dermatological conditions in dermatology need to consider in relation to drug route of administration across small molecule, biologic and mAb therapies?

• How can industry improve to accelerate the development of orally administered drugs?

3:00 pm Scientific Poster Session


The learning & networking continues! Join us for our new scienifitc poster session, providing an opportunity to connect with peers, fostering new relationships, and a platform for showcasing your work, while also allowing you to explore cutting-edge contributions across drugd iscovery to clinical trial updates.

3:45 pm Using Nanotechnology to Help Enhance Topical Drug Delivery: Scientific Successes & Regulatory Challenges

  • David Cook Chief Scientific Officer, Blueberry Therapeutics Ltd


• Putting patients at the heart of dermatology drug development: Optimising formulations to improve efficacy (drug delivery to target sites) / compliancy and improve patient quality of life

• Novel nanotechnology approach: Optimising formulations to improve drug targeting and delivery

• How regulatory environments impact formulation/excipient’s route to approval

Beyond Dermatology: Realising Opportunities for Disease with Inflammatory Components

4:15 pm Panel Session : Unlocking Synergies: Extending Dermatological Drug Development Insights to Address Broader Inflammatory Diseases


Gain insights into the extension of knowledge from immuno-dermatological drug development to encompass a broader range of inflammatory diseases, including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease and more:

• How can advancements in our mechanistic understanding of dermatological drug development interactions targeting inflammatory pathways be leveraged to benefit patients with other inflammatory diseases?

• What are the key challenges in translating dermatological drug discoveries into therapies for broader inflammatory conditions, such as rheumatoid arthritis or inflammatory bowel disease?

• How can we ensure that cross-pollination efforts align with the diverse needs and experiences of patients with various inflammatory conditions?

• What strategies and initiatives can facilitate greater collaboration and knowledge sharing in the field of dermatology and broader inflammatory diseases?

• How can these advancements in precision medicine and biomarker development in dermatology be extended to identify patient populations in other inflammatory diseases who are most likely to benefit from cross-pollinated therapies, ensuring more targeted treatment approaches?

5:00 pm Chair’s Closing Remarks & End of Day One